Geode Capital Management LLC grew its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 28.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,538,902 shares of the company's stock after purchasing an additional 339,846 shares during the period. Geode Capital Management LLC owned about 2.25% of EyePoint Pharmaceuticals worth $11,467,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in EyePoint Pharmaceuticals by 24.8% during the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock valued at $28,334,000 after purchasing an additional 755,045 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of EyePoint Pharmaceuticals by 9.9% in the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after acquiring an additional 362,399 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of EyePoint Pharmaceuticals by 1,171.3% in the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock valued at $2,970,000 after acquiring an additional 342,516 shares during the last quarter. abrdn plc acquired a new position in shares of EyePoint Pharmaceuticals in the 4th quarter worth approximately $1,719,000. Finally, Barclays PLC increased its holdings in EyePoint Pharmaceuticals by 410.4% during the 3rd quarter. Barclays PLC now owns 245,045 shares of the company's stock valued at $1,959,000 after purchasing an additional 197,033 shares in the last quarter. Institutional investors own 99.41% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the company. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price objective for the company. Finally, Chardan Capital reiterated a "buy" rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $26.63.
Read Our Latest Stock Report on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Stock Performance
EYPT opened at $6.51 on Wednesday. The company has a fifty day moving average price of $5.93 and a two-hundred day moving average price of $7.79. The firm has a market capitalization of $447.43 million, a PE ratio of -3.26 and a beta of 1.39. EyePoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $21.26.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The company had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Equities analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.
About EyePoint Pharmaceuticals
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
